A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease

(2017) Jotam G. Pasipanodya et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance

(2017) Shashikant Srivastava et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease

(2017) Devyani Deshpande et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease

(2016) Devyani Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases

(2016) Devyani Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

(2016) Shashikant Srivastava et al.   CLINICAL INFECTIOUS DISEASES

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground

(2016) Shashikant Srivastava et al.   CLINICAL INFECTIOUS DISEASES

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance

(2012) Aurelia M. Schmalstieg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and Treatment of Infections due toMycobacterium aviumComplex

(2008) Shannon Kasperbauer et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE